Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1978 Jan;61(1):150–162. doi: 10.1172/JCI108913

Characterization of the Binding of a Potent Synthetic Androgen, Methyltrienolone, to Human Tissues

Mani Menon 1,2, Catherine E Tananis 1,2, L Louise Hicks 1,2, Edward F Hawkins 1,2, Martin G McLoughlin 1,2, Patrick C Walsh 1,2
PMCID: PMC372523  PMID: 73547

Abstract

The potent synthetic androgen methytrienolone (R 1881), which does not bind to serum proteins, was utilized to characterize binding to receptors in human androgen responsive tissues. Cytosol extracts prepared from hypertrophic prostates (BPH) were utilized as the source of receptor for the initial studies. High affinity binding was detected in the cytosol of 29 of 30 samples of BPH (average number of binding sites, 45.8±4.7 fmol/mg of protein; dissociation constant, 0.9±0.2 nM). This binding had the characteristics of a receptor: heat lability, precipitability by 0-33% ammonium sulfate and by protamine sulfate, and 8S sedimentation coefficient. High affinity binding was also detected in cytosol prepared from seminal vesicle, epididymis, and genital skin but not in non-genital skin or muscle. However, similar binding was demonstrated in the cytosol of human uterus. The steroid specificities of binding to the cytosol of male tissues of accessory reproduction and of uterus were similar in that progestational agents were more effective competitors than natural androgens. Binding specificities in cytosol prepared from genital skin were distinctly different and were similar to those of ventral prostate from the castrated rat in that dihydrotestosterone was much more potent than progestins in competition. Thus binding of R 1881 to the cytosol of prostate, epididymis, and seminal vesicle has some characteristics of binding to a progesterone receptor.

When the nuclear extract from BPH was analyzed, high affinity binding was demonstrated that conformed to the specificities of binding to an androgen receptor. Here dihydrotestosterone was a more potent competitor than progestational agents. Similar patterns of binding were detected in the crude nuclear extracts from seminal vesicle, epididymis, and genital skin but not in uterus, muscle, or non-genital skin. We conclude that the androgen receptor is not demonstrable in the cytosol of prostate, epididymis, or seminal vesicle of non-castrated men but can be measured in the cytosol of genital skin and the nuclear extracts of androgen responsive tissues. Because steroid hormones exert their major influence within the nucleus of target tissues, the measurement of nuclear receptor may provide valuable insight into the regulation of growth of target tissues.

Full text

PDF
150

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asselin J., Labrie F., Gourdeau Y., Bonne C., Raynaud J. P. Binding of [3H] methyltrienolone (R 1881) in rat prostate and human benign prostatic hypertrophy (BPH). Steroids. 1976 Oct;28(4):449–459. doi: 10.1016/0039-128x(76)90014-3. [DOI] [PubMed] [Google Scholar]
  2. Bonne C., Raynaud J. P. Assay of androgen binding sites by exchange with methyltrienolone (R 1881). Steroids. 1976 Apr;27(4):497–507. doi: 10.1016/0039-128x(76)90084-2. [DOI] [PubMed] [Google Scholar]
  3. Bonne C., Raynaud J. P. Methyltrienolone, a specific ligand for cellular androgen receptors. Steroids. 1975 Aug;26(2):227–232. doi: 10.1016/s0039-128x(75)80023-7. [DOI] [PubMed] [Google Scholar]
  4. Bullock L. P., Barthe P. L., Mowszowicz I., Orth D. N., Bardin C. W. The effect of progestins on submaxillary gland epidermal growth factor: demonstration of androgenic, synandrogenic and antiandrogenic actions. Endocrinology. 1975 Jul;97(1):189–195. doi: 10.1210/endo-97-1-189. [DOI] [PubMed] [Google Scholar]
  5. Davies P., Griffiths K. Similarities between 5alpha-dihydrotestosterone-receptor complexes from human and rat prostatic tissue: effects on RNA polymerase activity. Mol Cell Endocrinol. 1975 Aug;3(2):143–164. doi: 10.1016/0303-7207(75)90060-x. [DOI] [PubMed] [Google Scholar]
  6. Geller J., Cantor T., Albert J. Evidence for a specific dihydrotestosterone-binding cytosol receptor in the human prostate. J Clin Endocrinol Metab. 1975 Nov;41(5):854–862. doi: 10.1210/jcem-41-5-854. [DOI] [PubMed] [Google Scholar]
  7. Hansson V., Tveter K. J., Unhjem O., Djöseland O. Studies on the interaction between androgen and macromolecules in male accessory sex organs of rat and man. J Steroid Biochem. 1972 Apr;3(3):427–439. doi: 10.1016/0022-4731(72)90089-1. [DOI] [PubMed] [Google Scholar]
  8. Jensen E. V., DeSombre E. R. Mechanism of action of the female sex hormones. Annu Rev Biochem. 1972;41:203–230. doi: 10.1146/annurev.bi.41.070172.001223. [DOI] [PubMed] [Google Scholar]
  9. Mainwaring W. I., Milroy E. J. Characterization of the specific androgen receptors in the human prostate gland. J Endocrinol. 1973 Jun;57(3):371–384. doi: 10.1677/joe.0.0570371. [DOI] [PubMed] [Google Scholar]
  10. Menon M., Tananis C. E., McLoughlin M. G., Lippman M. E., Walsh P. C. The measurement of androgen receptors in human prostatic tissue utilizing sucrose density centrifugation and a protamine precipitation assay. J Urol. 1977 Mar;117(3):309–312. doi: 10.1016/s0022-5347(17)58443-8. [DOI] [PubMed] [Google Scholar]
  11. Menon M., Tananis C. E., McLoughlin M. G., Walsh P. C. Androgen receptors in human prostatic tissues: a review. Cancer Treat Rep. 1977 Mar-Apr;61(2):265–271. [PubMed] [Google Scholar]
  12. Mowszowicz I., Bieber D. E., Chung K. W., Bullock L. P., Bardin C. W. Synandrogenic and antiandrogenic effect of progestins: comparison with nonprogestational antiandrogens. Endocrinology. 1974 Dec;95(6):1589–1599. doi: 10.1210/endo-95-6-1589. [DOI] [PubMed] [Google Scholar]
  13. Nijs M., Hawkins E. F., Coune A. Proceedings: Binding of 5 alpha-dihydrotestosterone in human prostatic cancer; examination by agar gel electrophoresis. J Endocrinol. 1976 Jun;69(3):18P–19P. [PubMed] [Google Scholar]
  14. Siiteri P. K., Wilson J. D. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest. 1970 Sep;49(9):1737–1745. doi: 10.1172/JCI106391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Steins P., Krieg M., Hollmann H. J., Voigt K. D. In vitro studies of testosterone and 5alpha-dihydrotestosterone binding in benign prostatic hypertrophy. Acta Endocrinol (Copenh) 1974 Apr;75(4):773–784. doi: 10.1530/acta.0.0750773. [DOI] [PubMed] [Google Scholar]
  16. Toft D., O'Malley B. W. Target tissue receptors for progesterone: the influence of estrogen treatment. Endocrinology. 1972 Apr;90(4):1041–1045. doi: 10.1210/endo-90-4-1041. [DOI] [PubMed] [Google Scholar]
  17. Van Doorn E., Craven S., Bruchovsky N. The relationship between adrogen receptors and the hormonally controlled responses of rat ventral prostate. Biochem J. 1976 Oct 15;160(1):11–21. doi: 10.1042/bj1600011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Walsh P. C. Physiologic basis for hormonal theapy in carcinoma of the prostate. Urol Clin North Am. 1975 Feb;2(1):125–140. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES